Principia Biopharma (Principia Biopharma) Total Inventories : $0.00 Mil (As of Jun. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Principia Biopharma Total Inventories?

Principia Biopharma's total inventories for the quarter that ended in Jun. 2020 was $0.00 Mil. Principia Biopharma's average total inventories from the quarter that ended in Mar. 2020 to the quarter that ended in Jun. 2020 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Principia Biopharma's Net-Net Working Capital per share for the quarter that ended in Jun. 2020 was $8.50.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Principia Biopharma's Inventory-to-Revenue for the quarter that ended in Jun. 2020 was 0.00.

Principia Biopharma Total Inventories Historical Data

The historical data trend for Principia Biopharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Principia Biopharma Total Inventories Chart

Principia Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Total Inventories

Principia Biopharma Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Total Inventories	Get a 7-Day Free Trial								-	-	-	-	-

Principia Biopharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Principia Biopharma (NAS:PRNB) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Principia Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2020 is

	Net-Net Working Capital Per Share (Q: Jun. 2020 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(316.533	+	0.75 * 0	+	0.5 * 0	-	34.514
-	0	-	0)	/	33.1613
=	8.50

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Principia Biopharma's Days Inventory for the three months ended in Jun. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2020 )	/	Cost of Goods Sold (Q: Jun. 2020 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Principia Biopharma's Inventory Turnover for the quarter that ended in Jun. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2020 )	/	Average Total Inventories (Q: Jun. 2020 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Principia Biopharma's Inventory to Revenue for the quarter that ended in Jun. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2020 )	/	Revenue (Q: Jun. 2020 )
	=	0	/	50
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Principia Biopharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Principia Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Principia Biopharma (Principia Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

220 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.principiabio.com

Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.

Executives

Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Stefani Wolff	officer: Chief Development Officer	C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Daniel J. Becker	director	C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Martin Babler	director, officer: President, CEO	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Dolca Thomas	officer: Chief Medical Officer	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alan Colowick	director	C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
Shao-lee Lin	director	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
David M Goldstein	officer: Chief Scientific Officer	C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Roy C. Hardiman	officer: Chief Business Officer	C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Christopher Y Chai	officer: Chief Financial Officer	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104